18F-Alfatide - Yantai LNC Biotechnology
Alternative Names: 18-F-LNC1016; 18F-Alfatide Injection; 18F-Alfatide-Yantai LNC BiotechnologyLatest Information Update: 08 Jul 2024
At a glance
- Originator Yantai LNC Biotechnology
- Class Antineoplastics; Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Non-small cell lung cancer
Most Recent Events
- 24 May 2024 Clinical trials in Non-small cell lung cancer (IV, Injection)
- 16 May 2024 Yantai LNC Biotechnology plans a phase III trial for Non-small cell lung cancer (Diagnosis) in China (IV, Injection) in August 2024 (NCT06416852)